Skip to content

MoonLake Immunotherapeutics

US · MLTX #3305 by market cap Listed 2020
10.77 -0.18 -1.64%
Live - 5344 symbols - heartbeat 268s ago · 2026-10-08 08:42
Pre-market 10.75 -0.19%
After-hours 10.96 +1.76%
Market cap
916.60M
P/B
2.14
EPS
-3.53
Reader sentiment Are you bullish or bearish on MLTX?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    Citi Maintains MoonLake Immunotherapeutics(MLTX.US) With Sell Rating, Maintains Target Price $6
    Market Newswire · 2026/3/20
  • Rating change
    Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Neumora Therapeutics, Inc. (NMRA) and Aurinia Pharmaceuticals (AUPH)
    TipRanks · 2026/3/31
  • LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $33
    Market Newswire · 2026/10/1
  • Rating change
    H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $50
    Market Newswire · 2026/8/13
  • Rating change
    H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $40
    Market Newswire · 2026/4/15
  • TD Cowen Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating
    Market Newswire · 2026/10/2
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Hinge Health, Inc. Class A (HNGE) and MoonLake Immunotherapeutics (MLTX)
    TipRanks · 2026/6/8
  • Rating change
    Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $25
    Market Newswire · 2026/4/14
  • H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $50
    Market Newswire · 2026/10/5
  • Rating change
    A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $12 to $70
    Market Newswire · 2026/5/11
  • Rating change
    A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $30 to $70
    Market Newswire · 2026/6/23
  • Leerink Partners Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $30
    Market Newswire · 2026/10/2
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Artiva Biotherapeutics, Inc. (ARTV), MoonLake Immunotherapeutics (MLTX) and MBX Biosciences, Inc. (MBX)
    TipRanks · 2026/6/9
  • Rating change
    H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $45
    Market Newswire · 2026/7/20
  • Rating change
    BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/4/8
  • Wedbush Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $34
    Market Newswire · 2026/10/5
  • Rating change
    Wolfe Research Upgrades MoonLake Immunotherapeutics(MLTX.US) to Buy Rating, Announces Target Price $24
    Market Newswire · 2026/3/23
  • Rating change
    A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $30 to $34
    Market Newswire · 2026/8/11
  • Rating change
    A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $12 to $45
    Market Newswire · 2026/5/12
  • Rating change
    Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/6/9

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 08:42:36 · For reference only, not investment advice and not tailored to your situation.